These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31725005)

  • 1. Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. CON: Novel oral agents provide an attractive alternative to chemotherapy in metastatic hormone-sensitive prostate cancer.
    Condon B; Liskaser G; Thangasamy IA; Murphy DG
    Curr Opin Urol; 2020 Jul; 30(4):620-622. PubMed ID: 31725005
    [No Abstract]   [Full Text] [Related]  

  • 2. [The modern treatment of metastatic castration-resistant prostate cancer].
    Küronya Z; Biró K; Maráz A; Géczi L
    Magy Onkol; 2019 Mar; 63(1):41-50. PubMed ID: 30889620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.
    Hung J; Taylor AR; Divine GW; Hafron JM; Hwang C
    Clin Genitourin Cancer; 2016 Oct; 14(5):381-388. PubMed ID: 27157640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.
    Bambury RM; Rathkopf DE
    Urol Oncol; 2016 Aug; 34(8):348-55. PubMed ID: 26162486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current understanding of resistance to abiraterone  and enzalutamide in advanced prostate cancer.
    Antonarakis ES
    Clin Adv Hematol Oncol; 2016 May; 14(5):316-9. PubMed ID: 27379691
    [No Abstract]   [Full Text] [Related]  

  • 6. [Hormone therapy in prostate cancer; a pharmacotherapeutic challenge].
    Westdorp H; Benoist GE; Schers HJ; van Erp PH; Gerritsen WR; Mulders PF; Kramers C
    Ned Tijdschr Geneeskd; 2015; 159():A9250. PubMed ID: 26246066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy.
    Tombal B
    Eur Urol; 2015 Aug; 68(2):236-7. PubMed ID: 24908474
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
    Attard G; Antonarakis ES
    Nat Rev Urol; 2016 Dec; 13(12):697-698. PubMed ID: 27804988
    [No Abstract]   [Full Text] [Related]  

  • 10. New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis.
    Marchioni M; Di Nicola M; Primiceri G; Novara G; Castellan P; Paul AK; Veccia A; Autorino R; Cindolo L; Schips L
    J Urol; 2020 Apr; 203(4):751-759. PubMed ID: 31689158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents.
    Bando Y; Hinata N; Terakawa T; Furukawa J; Harada KI; Nakano Y; Fujisawa M
    Med Oncol; 2017 Aug; 34(9):163. PubMed ID: 28819719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzalutamide before chemotherapy prolongs survival.
    Cancer Discov; 2014 Jul; 4(7):OF5. PubMed ID: 25002634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Primary in Metastatic Prostate Cancer: What Is the Standard of Care?
    Joseph N; Anjanappa M; Choudhury A
    Cancer J; 2020; 26(1):83-86. PubMed ID: 31977390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastasis: Resistance fighters.
    Savage N
    Nature; 2015 Dec; 528(7582):S128-9. PubMed ID: 26672785
    [No Abstract]   [Full Text] [Related]  

  • 15. Secondary hormone therapy for castration-resistant prostate cancer.
    Taplin ME
    Oncology (Williston Park); 2013 May; 27(5):371-2. PubMed ID: 25184257
    [No Abstract]   [Full Text] [Related]  

  • 16. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
    Zhang T; Zhu J; George DJ; Armstrong AJ
    Expert Opin Pharmacother; 2015 Mar; 16(4):473-85. PubMed ID: 25534660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors to Guide Treatment Selection for Hormone-Sensitive Metastatic Prostate Cancer.
    Tsao PA; Caram MEV
    Cancer J; 2020; 26(1):76-82. PubMed ID: 31977389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline DNA-repair Gene Mutations and Efficacy of Abiraterone or Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.
    Shao N; Zhu Y; Ye DW
    Eur Urol Focus; 2019 Sep; 5(5):745-747. PubMed ID: 30797739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Hormonal Agents in Patients with Nonmetastatic Castration-resistant Prostate Cancer: Can We Be Satisfied with an Advantage in Metastasis-free Survival?
    Di Nunno V; Santoni M; Massari F
    Eur Urol Oncol; 2019 Jul; 2(4):471. PubMed ID: 31277785
    [No Abstract]   [Full Text] [Related]  

  • 20. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated: © NICE (2016) Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.
    BJU Int; 2017 Aug; 120(2):168-184. PubMed ID: 28719114
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.